Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This Phase 3 open-label single-arm study is designed to investigate the safety, diagnostic
performance, and clinical usefulness of Gleolan for the real time detection and visualization
of meningiomas during tumor resection surgery. The study is planned to run for 15 months with
individual study participation lasting for approximately 2 months.